Abstract
Patients with sepsis commonly suffer from coagulation dysfunction and lead to the formation of thrombus. During the development of sepsis, neutrophils migrate from the circulating blood to infected tissues and mediate the formation of neutrophil extracellular traps (NETs) that kill pathogens. However, the overactivation of neutrophils can promote the formation of immunothrombosis and even cause disseminated intravascular coagulation (DIC), which damages microcirculation. The outcome of sepsis depends on early recognition and intervention, so clinical evaluation of NETs function may be a valuable biomarker for early diagnosis of sepsis. The interaction of NETs with platelets, complement, and endothelium mediates the formation of immunothrombosis in sepsis. Inhibiting the formation of NETs is also considered to be one of the potential treatments for sepsis. In this review, we will discuss the key role of neutrophils and NETs in sepsis and septic thrombosis, in order to reveal new mechanisms for thrombosis treatment of sepsis.
Introduction
Sepsis is a life-threatening organ dysfunction caused by a disordered response to infection (Singer et al., 2016). In 2017, the incidence of global sepsis was estimated to be 48.9 million, of which the death toll related to sepsis was as high as 11 million (). In early sepsis, multiple pathophysiological processes exist simultaneously, such as inflammation and coagulation activation (). The coagulation cascade is a complex process, and changes in patients’ coagulation function during sepsis is a predictor of poor prognosis (). The host will activate blood clotting in the process of defending against infectious pathogens. However, an excessive activation of the coagulation system along with vascular endothelial damage will cause the formation of microvascular thrombus and lead to multiorgan dysfunction (). An hyperactivated and dysfunctional coagulation system will also manifest as consumption of anticoagulant factors, inhibition of the fibrinolytic system, significant shortening of clot formation kinetics (CFT), and increase clot firmness (CF) (). As a pro-inflammatory mediator, thrombin, a critical mediator of the coagulation cascade in sepsis, can activate receptors through specific proteases to stimulate monocytes and endothelial cells (ECs).
As the most abundant white blood cell group in humans, neutrophils play an essential role in the body’s innate immunity caused by infection. An excessive activation of neutrophils can lead to the development of multiple organ dysfunction syndromes (). In sepsis, pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) can activate pattern recognition receptors (PRRs) located in neutrophils (). In these cells, those molecules will stimulate cell migration from circulating blood to infected tissues. Then, neutrophils will release intracellular granular components, including myeloperoxidase (MPO), neutrophil elastase (NE), and cathepsin G. Activated neutrophils will also release nuclear DNA and form a network structure containing nucleus, cytoplasm, and granular protein, also known as the neutrophil extracellular traps (NETs) (). NETs mediate the killing process of bacteria, viruses (; ) and fungi (Urban et al., 2006), however, their dysfunction will result in inability to fight infection, which is evidenced in patients with severe COVID-19 (). Excessive NETs formation can damage the microcirculation, promote immunothrombosis and lead to diffuse intravascular coagulation as they facilitate the formation of thrombus as a scaffold for thrombosis (Thomas et al., 2012).
In summary, NETs can eliminate pathogens by mediating neutrophils, but their hyperfunction will also cause tissue damage (). In this review, we will discuss the key role of neutrophils and NETs in sepsis and sepsis thrombosis, to reveal new mechanisms for sepsis treatment.
The Formation of NETs
In 1971, Lerner first discovered the important role of neutrophils in the process of thrombosis (). But it was not until 2004 when Brinkmann and others suggested the concept of NETs ().
Neutrophils can activate NADPH oxidase through protein kinase C (PKC) and Raf-MEK-ERK signaling pathways to produce reactive oxygen species (ROS). ROS-activated peptidylarginine deiminase 4 (PAD4) modifies specific arginine residues on histones H3 and H4 (Wang et al., 2004) to make linker histone H1 and heterochromatin protein 1b dissociates from the nucleosome structure (), which mediates the dedensification of chromatin. MPO, NE, and cathepsin G promote further depolymerization of chromatin, thereby destroying the nuclear membrane (). The chromatin is released into the cytoplasm as DAMP to further activate the immune response and form NETs. Treatment with DNase can significantly destroy the structure of NETs (). The formation of NETs often leads to death of neutrophil, and this process is called NETosis (Vorobjeva and Chernyak, 2020). NETs can be formed in various parts of the body, and NETs can be released wherever neutrophils exist. Therefore, when sepsis occurs, neutrophils are present in different organs, such as the lung, liver, intestine, kidney, heart, and other organs, as well as in the blood circulation throughout the body. And the interaction of platelets, endothelial cells and complement can mediate the formation of NETs and immunothrombosis.
Markers of NETs
The outcome of sepsis depends on early diagnosis and intervention. Thus, it has been suggested that early recognition of NETs may be a valuable biomarker of early sepsis. The degree of NETs formation is significantly related to the severity of the disease, and can independently predict the development of diffuse intravascular coagulation (DIC) and mortality (). Cell free DNA (cfDNA), NETs related MPO-DNA complex, citrullinated-histone H3-DNA (cit-H3-DNA) complex and deoxyribonuclease I (DNase I) can indirectly reflect NETs formation in the blood of patients with sepsis (Wang et al., 2016). For instance, cit-H3-DNA is also associated with NETs in patients with severe respiratory infections (). Also, DNA release, elastase production and inflammatory cytokines can affect the severity and organ failure of patients with sepsis ().
These markers have the potential to detect NETs, although they are not directly achieved by detecting NETs. At the same time, some markers are not only related to NETs, but also related to infections caused by other mechanisms. For example, the concentration of cfDNA in plasma can activate the nucleic acid sensing pathway to generate inflammation, and participate in the formation of sepsis (). In addition, the circulating concentration of some markers is unstable, lacking detection sensitivity and specificity.
found that co-incubation of neutrophils with the plasma or serum of patients with sepsis can directly induce the production of NETs. Compared with healthy volunteers, the plasma of patients with sepsis can cause a large number of NETs, and the degree of plasma NETs in patients with thrombocytopenia, abnormal prothrombin time, activated partial thromboplastin time, fibrinogen, and D-dimer are closely related. Therefore, these indicators can also be used as indirect means to reflex NETs (; ). Correctly detecting the formation of NETs is essential for identifying early sepsis.
Factors in NETs-Associated Thrombosis
Vascular Endothelium
The integrity of endothelial structure and function is the key to maintaining vascular homeostasis. Endothelial injury plays an important role in thrombosis. In the development of sepsis, neutrophils are recruited to the site of inflammation through rolling, activation, firm attachment, and extravasation on ECs (). The rolling of neutrophils on activated ECs is caused by the action of P-selectin and P-selectin glycoprotein ligand 1 (PSGL-1). By activating integrin αLβ2 (LFA-1) and binding to intercellular adhesion molecule 1 (ICAM-1), P-selectin participates in the further rolling and firm adhesion of neutrophils. Through the interaction between CXC chemokine ligand 1 (CXCL1) and its receptor CXC chemokine 2 (CXCR2), neutrophils are recruited to the site of inflammation ().
In septic-infected mice, the release of extracellular histones led to infiltration of neutrophils, vacuolation of ECs, intra-alveolar hemorrhage, and vascular thrombosis (Xu et al., 2009). When ICAM-1 inhibitors inhibited the homing of neutrophils to ECs, thrombosis in mice was reduced. NETs promote the activation of ECs and increase thrombosis through the synergistic effect of IL-1α and cathepsin G (). Matrix metalloproteinases-9 (MMPs-9) in NETs can activate MMP-2 of ECs and cause endothelial dysfunction (). NETs can induce ECs to release adhesion factors and tissue factor (TF), further recruit inflammatory cells, and promote thrombosis (). In sepsis, lipopolysaccharide (LPS) induces the activation of peptidylarginine deiminase (PAD) and the formation of NETs mediated by the PAD-NET-CitH3 pathway, which changes the permeability of the pulmonary vascular endothelium (). The induction of ECs by NETs also has two sides. Low concentrations of NETs can promote the release of inflammatory factors from ECs through the TLR4/NF-κB signaling pathway (), and NETs can also induce death of ECs in a dose-dependent manner (). NETs can amplify endothelial dysfunction associated with thrombosis. Vascular endothelium plays an important role in the occurrence and development of thrombus in sepsis.
Platelets
Platelets play an essential role in coagulation (van der Meijden and Heemskerk, 2019). Platelets can recruit leukocytes to the site of infection in the early stages of sepsis. Platelet activation induced by pathogens and platelet agonists, such as thrombin, arachidonic acid, collagen, or ADP can mediate the development of procoagulant, prothrombotic and inflammation, and ultimately lead to vascular endothelium damage. Activated platelets can also roll and adhere to the surface of neutrophils to form aggregates and enhance their ability to kill pathogens (; ). NETs further promote platelet adhesion, activation, aggregation, and exert procoagulant activity, thereby providing a scaffold for thrombosis (), forming positive feedback activation of coagulation. NETs can also recruit red blood cells, promote von Willebrand Factor (VWF), fibrinogen and fibrin deposition, thereby inducing venous thrombosis ().
Sepsis is usually accompanied by thrombocytopenia and occlusion of small blood vessels, called disseminated intravascular coagulation (DIC). The substances produced by NETs can either diffuse throughout the interstitium of organs, or be released into the vascular lumen and attach to the vascular wall of narrow capillaries (). In the mouse model of pneumonia caused by sepsis, thrombocytopenia usually worsened sepsis, led to increased bacterial growth in the blood and lungs, and reduced the survival rate of animals ().
LPS can initiate the non-classical activation of platelets, and activate TLR4 on platelets which will also lead to the release of the NETs (). The activation of platelets by LPS can induce platelet-dependent tissue factor pro-coagulant activity (TF-PCA) and promote the production of thrombin in a TLR4-dependent manner (). As one of the substances released by NETs, histones can induce the production of thrombin ().
To a certain extent, NETs can trigger pro-thrombotic and pro-coagulant platelet-mediated responses by interacting with TLR4. As a key receptor, TLR4 on platelets may be an important factor in septic DIC (Semeraro et al., 2011). In septic mice, neutrophils adhere to the endothelial cells of the lung and liver sinusoids, and platelets activated by LPS can stick to neutrophils to promote the production of NETs (). The α-toxin produced by Staphylococcus aureus can bind to A disintegrin and metalloprotease 10 (ADAM10), which also causes the activation of platelets and neutrophils, and the formation of platelet-neutrophil aggregates (). In addition, intravenous injection of α-toxin can rapidly accumulate platelets and form thrombus in the liver sinusoids and glomeruli through GPIb, leading to multiple organ dysfunction (Surewaard et al., 2018). In COVID-19 patients, it was also found that the expression of P-selectin increased, and the aggregation of platelets-neutrophils and monocytes increased () which was associated to thrombotic complications. Therefore, platelets play an important role in abnormal blood coagulation caused by sepsis (Figure 1).
Figure 1
Complement
In recent years, it has been discovered that NETs can activate three different complement pathways to form thrombosis. The complement system is stimulated by active coagulation factors, causing the immune system to recruit neutrophils (). The complement system is composed of serine-protease cascade reactions, including the continuous cleavage of complement proteins, which ultimately leads to the formation of membrane attack complex (MAC) ().
Complement C3 is an important mediator in the complement system and activates neutrophils during sepsis (Yuen et al., 2016). Neutrophils from C3a receptor (C3aR) -deficient mice cannot form NETs. When C3 containing serum from healthy mice is exogenously administered, their function is restored. This shows that complement is closely related to the formation of NETs (Yipp et al., 2012). Blocking the complement receptor 3 (CR3) that binds to opsonin iC3b can inhibit NETosis (). C3b, as an important upstream component to generate MAC, has also been found in NETs (). On PMA-induced NETs, Factor B and C3 deposition have been found, and the combination of C1q and NETs can prevent itself from being degraded by DNase I (). Thereby maintaining the structure of NETs (; ). Complement C5a can recruit and activate neutrophils, leading to the up-regulation of immune receptors such as Toll-like receptors (TLR) and complement receptors (Wang et al., 2015). In addition, using C5a to pre-stimulate neutrophils enhanced their ability to generate NETs (Wang et al., 2015). The complement molecules in the blood can be deposited on NETs and continue to function. Properdin, Factor B and C3 have all been found to exist on NETs and exert their blood coagulation and antibacterial functions (Yousefi et al., 2009) (Figure 2).
Figure 2
Immunothrombosis
In recent years, researchers have proposed that there may be an effect mechanism in the link between blood coagulation and innate immune response that mediates the formation of immunothrombosis. Initially, NETs were found in patients’ arterial or venous thrombosis. Researchers gradually realized that NETs provide a scaffold to recruit red blood cells, platelets, white blood cells, as well as bind plasma proteins. The aggregation of NETs in the coronary arteries suggested that NETs might contribute to the growth and stability of thrombus (). By analyzing ischemic stroke thrombosis, DNA, MPO and citrullinated histone H4 were found to be positive for triple co-staining, and NETs were abundant in different types of stroke thrombosis (). Infection accelerates neutrophils recruitment and activation, leading to a more pronounced involvement of NETs in thrombosis. In patients with abdominal aortic aneurysm infected with Porphyromonas gingivalis, the recruitment of neutrophils and the formation of NETs were increased, and wound healing was inhibited (). Infection-driven NETs formation also leads to pulmonary thrombosis associated with sepsis (). Because NETs can stimulate fiber remodeling, NETs may promote the development of venous thrombosis (). NETs may also be a prethrombotic lesion and play a key role in thrombosis.
The coagulation system is activated by pathogens and helps the host defend against infection by reducing the spread of pathogens and killing them (). Immunothrombosis can mediate the identification of pathogens and damaged cells, and inhibit the spread and survival of pathogens. This phenomenon also exists in sepsis. Neutrophils promote the capture and degradation of pathogens through the NETosis pathway, and the decondensed chromatin and antibacterial proteins are released from neutrophils to form NETs. Through the release of NETs, neutrophils participate in the formation of immunothrombosis. Intravascular coagulation induced by NETs resulted in extensive microvascular occlusion and multiple organ failure in a variety of sepsis mouse models ().
The presence of senescent and pro-inflammatory neutrophils in the circulation of miR-146a-deficient mice leads to increased thrombosis in the LPS-induced sepsis model (). Exposure of the endothelium to pathogens and PAMP triggers a pre-adhesion phenotype that leads to neutrophil binding. NF-κB signal is involved in the circulatory process of thrombus and inflammation (). Neutrophils can secrete molecules that promote the initiation of the coagulation cascade (), and TF plays an important role in this process (Smadja, 2014).
The two-way effect of NETs and platelets represents the connection between these phenomena. Whether in infectious or non-infectious diseases, the interaction of platelets and neutrophils is crucial (), and constitutes a vicious circle in the process of immunothrombosis Therefore, immunothrombosis may be an important physiological process of intravascular immunity, and its imbalance may be one of the potential events that trigger thrombotic diseases and lead to intravascular coagulation in sepsis.
Potential Therapeutic Targets
Although NETs are increasingly recognized as important therapeutic targets, there is currently no clear drug that regulates NETs to guide the treatment of sepsis and sepsis-related thrombosis. Several potential targets of NETs are listed below.
TLR4 Blocker
The downstream reaction caused by the combination of TLR4 and LPS is one of the classic pathways of sepsis. In addition, TLR4 on platelets is also involved in the induction of NETs in mice and humans (). TLR4-/- septic mice did not enhance the thrombotic response, and circulating ICAM-1 was significantly reduced (). Inhibition of TLR4 can improve the prognosis of sepsis (), so TLR4 blockers may be used as a potential new method for the treatment of sepsis. 2-acetamidopyranoside compound (MW 389) acts as a TLR blocker to inhibit the production of TNF-α and iNOS RNA in a mouse model of LPS-induced sepsis (). In addition, statins, and angiotensin receptor blockers (ARBs) have been found to have inhibitory activity on the TLR4 signaling pathway. Fluvastatin, simvastatin and atorvastatin showed effective inhibition of the TLR4 pathway (). Candesartan can inhibit the activation of TLR4 induced by LPS (), and valsartan of the angiotensin-receptor blocker family (Yang et al., 2009) has been shown to reduce the release of pro-inflammatory cytokines by inhibiting TLR4 signaling. TAK-242 (resatorvid) is a small molecule specific inhibitor of TLR4. By binding to the intracellular domain of TLR4, it disrupts the interaction between TLR4 and adaptor molecules, thereby inhibiting TLR4 signal transduction and preventing the production of inflammatory mediators induced by LPS (). However, in large-scale clinical trials, TAK-242 failed to suppress cytokine levels in patients with sepsis, shock, or respiratory failure (). Even if drugs are given in the early stages of sepsis, when sepsis is diagnosed, there is already an inflammatory response that cannot be suppressed. Therefore, it may be more important to recognize the signs of sepsis and prevent them in time.
As a ligand of LPS, TLR4 can prevent the cascade of inflammation by intervening in the early stage of sepsis, but its complete blockade may also lose the body’s innate immune response to endotoxin. Therefore, it is still necessary to consider the pros and cons of its use before putting it into clinical use.
PAD4 Inhibitors
Overexpression of peptidyl arginine deiminase 4 (PAD4) leads to the elimination of chromatin and the release of NETs in cells in vitro. PAD4 causes the loss of the positive charge on the arginine guanidine group and unfolds the DNA strand to form NETs. PAD4 plays an important role in the formation of NETs (). Therefore, the activation of PAD4 may be one of the targets of NETs formation. In a sepsis model, PAD4 knockout mice showed improved survival rate, reduced severity of organ dysfunction, and lower development of sepsis (). PAD4 inhibitor BB-Cl-amidine can protect NETs-mediated vascular injury and endothelial dysfunction in mouse models (). Perdomo et al. found that thrombocytopenia and thrombosis are two separable processes. Even in the absence of NETs, heparin may also lead to the reduction of platelets. Knockout of PAD4 or use of PAD4 inhibitor GSK484 will inhibit heparin-induced thrombocytopenia/thrombosis (HIT) thrombocytopenia and thrombosis (). PAD4 inhibitor GSK484 can also affect kindlin-3 in mouse neutrophils and inhibit thrombosis caused by NETs (Yan et al., 2019). The PAD4 inhibitor Cl-amidine affects endothelial function and prethrombotic phenotype by blocking NETs (), and can also inhibit tissue damage associated with inflammatory bowel disease mouse models (). Therefore, PAD4 may be one of the potential targets to inhibit the formation of NETs, which can interfere with thrombosis caused by inflammation without affecting the coagulation system.
Heparin
The role of heparin therapy in anticoagulation is unquestionable. However, the treatment of thrombus caused by heparin in NETs is still controversial. Low-dose heparin (250U/kg) treatment can reduce the expression of NETs, histones, and pro-inflammatory factors (Sun et al., 2020). A large amount of heparin will produce antibodies against platelet factor 4 (PF4) and heparin complexes, leading to excessive activation of coagulation to activate platelets and promote thrombosis (). In addition, heparin can directly induce the formation of NETs, but NETs cannot be induced by low molecular weight heparin, heparin analogs or heparin sulfate [low molecular weight heparin(LMWH), heparin mimetics or heparan sulfate] (). However, there are also reports in the literature that heparin and heparin-derived drugs (including unfractionated heparin, LMWH and occasionally fondaparinux) can induce immune responses, leading to HIT (). This suggests that we need to pay attention to the dosage when using heparin in clinical practice, or use heparin substitutes for anticoagulation therapy to avoid activating NETs.
Other Treatments
In septic patients, the concentration of IL-8 is closely related to the formation of NETs. IL-8 activation of mitogen-activated protein kinase is one of the main pathways for the formation of NETs in patients. Inhibition of IL-8 can significantly reduce NETosis (). Histones can activate neutrophils to form a network, and recombinant thrombomodulin (rTM) can inhibit the formation of NETs induced by histones ().
There is a dynamic platelet thrombin axis in sepsis, which promotes intravascular coagulation and microvascular dysfunction. DNase can inhibit the formation of NETs by degrading DNA. DNase1 and DNase1-like 3 can be expressed independently, degrade NETs in sterile neutrophilemia and sepsis, provide double protection, and protect the host from the harmful effects of intravascular NETs (). Elimination of NETs by infusion of DNase, or in mice deficient in NETs formation caused by PAD4 deficiency, can be found to significantly reduce thrombin activity, platelet aggregation and improve microvascular perfusion (). A summary of potential targets for NETs therapy is shown in Table 1.
Table 1
| Mechanism | Drug | References |
|---|---|---|
| TLR4 blocking agent | MW 389 | () |
| Statins (Fluvastatin, Simvastatin, Atorvastatin) | () | |
| ARBs (Candesartan, Valsartan) | (; Yang et al., 2009) | |
| TAK-242 | () | |
| PAD4 inhibitor | BB-Cl-amidine | () |
| GSK484 | () | |
| Cl-amidine | () | |
| Heparin | Low-dose heparin | (Sun et al., 2020) |
| Anti–IL-8 | Anti–IL-8 blocking mAb | () |
| Prevent histone-induced NETs formation | Recombinant thrombomodulin | () |
| Degrade DNA in NETs | DNase1 | () |
| DNase1-like 3 | () |
Potential targets for NETs therapy.
Conclusion
NETs have been confirmed to be related to inflammation, infection, and autoimmune diseases, and play an important role in sepsis and thrombosis caused by sepsis. NETs can not only play a role in immune defense in the inflammatory response, on the other hand, their excessive activation can also lead to a strong immune response and cause adverse consequences. In sepsis, NETs mainly through the interaction of neutrophils and platelets, leading to the functional damage of vascular ECs and the formation of immunothrombosis, further promoting the occurrence of microcirculation disorders.
The existence of NETs suggests that in the treatment of sepsis, whether a new method can be used to avoid excessive activation of inflammation and prevent the further occurrence of sepsis without affecting blood coagulation. By detecting the formation potential of NETs in the peripheral circulation, it can be used clinically to identify patients at risk of DIC and poor prognosis of sepsis. Based on the evidence that NETs and platelets interact to promote intravascular coagulation and its diffusion, we believe that the early recognition of NETs in sepsis can prompt early treatment of sepsis and DIC high-risk patients, and also provide a new direction for its treatment.
Funding
This research was supported by the National Key Research and Development Program of China (NO. 2020YFC2008400), the National Natural Science Foundation of China (NO.81873948, 81871591), Clinical Research Plan of SHDC (NO. SHDC2020CR4064, SHDC2020CR1005A), Shanghai Shenkang hospital development center, clinical science and technology innovation project (NO. SHDC12018105), 2019 Fudan University Zhuo-Xue Project (NO. JIF159607); Shanghai Sailing Program (No. 20YF1418400); Shanghai Leading Talent (NO: 2019-112).
Statements
Author contributions
ZC, HZ, WC, and CM provided the conception and the structure of the article. ZC wrote the draft. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbramsS. T.MortonB.AlhamdiY.AlsabaniM.LaneS.WeltersI. D.et al. (2019). A Novel Assay for Neutrophil Extracellular Trap Formation Independently Predicts Disseminated Intravascular Coagulation and Mortality in Critically Ill Patients. Am. J. Resp. Crit. Care200 (7), 869–880. doi: 10.1164/rccm.201811-2111OC
2
AdamikB.GozdzikW.JakubczykD.WelnaM.KüblerA. (2017). Coagulation abnormalities identified by thromboelastometry in patients with severe sepsis. Blood Coagul. Fibrin.28 (2), 163–170. doi: 10.1097/MBC.0000000000000572
3
AldabbousL.Abdul-SalamV.McKinnonT.DulucL.Pepke-ZabaJ.SouthwoodM.et al. (2016). Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension. Arterioscler. Thromb. Vasc. Biol.36 (10), 2078–2087. doi: 10.1161/ATVBAHA.116.307634
4
ArroyoA. B.Fernández-PérezM. P.MonteA. D.ÁguilaS.MéndezR.Hernández-AntolínR.et al. (2020). miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. Haematologica. doi: 10.3324/haematol.2019.240226
5
BehnenM.LeschczykC.MollerS.BatelT.KlingerM.SolbachW.et al. (2014). Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via FcgammaRIIIB and Mac-1. J. Immunol.193 (4), 1954–1965. doi: 10.4049/jimmunol.1400478
6
BerendsE. T.KuipersA.RaveslootM. M.UrbanusR. T.RooijakkersS. H. (2014). Bacteria under stress by complement and coagulation. Fems. Microbiol. Rev.38 (6), 1146–1171. doi: 10.1111/1574-6976.12080
7
Bhanu Kanth ManneF. D. E. A. (2020). Platelet gene expression and function in COVID-19 patients. Blood136 (11), 1317–1329. doi: 10.1182/blood.2020007214
8
Binita ShresthaT. I. (2019). Recombinant Thrombomodulin Suppresses Histone-Induced Neutrophil Extracellular Trap Formation. Front. Immunol.10, 2535. doi: 10.3389/fimmu.2019.02535
9
BironB. M.ChungC. S.ChenY.WilsonZ.FallonE. A.ReichnerJ. S.et al. (2018). PAD4 Deficiency Leads to Decreased Organ Dysfunction and Improved Survival in a Dual Insult Model of Hemorrhagic Shock and Sepsis. J. Immunol.123 (1), 33–42. doi: 10.1161/CIRCRESAHA.117.312494
10
BothaA. J.MooreF. A.MooreE. E.SauaiaA.BanerjeeA.PetersonV. M. (1995). Early neutrophil sequestration after injury: a pathogenic mechanism for multiple organ failure. J. Trauma.39 (3), 411–417. doi: 10.1097/00005373-199509000-00003
11
BrinkmannV. (2004). Neutrophil Extracellular Traps Kill Bacteria. Science303 (5663), 1532–1535. doi: 10.1126/science.1092385
12
CarestiaA.KaufmanT.SchattnerM. (2016). Platelets: New Bricks in the Building of Neutrophil Extracellular Traps. Front. Immunol.7, 271. doi: 10.3389/fimmu.2016.00271
13
Carmona-RiveraC.ZhaoW.YalavarthiS.KaplanM. J. (2015). Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann. Rheumatol. Dis.74 (7), 1417–1424. doi: 10.1136/annrheumdis-2013-204837
14
CecconiM.EvansL.LevyM.RhodesA. (2018). Sepsis and septic shock. Lancet392, 10141,75–87. doi: 10.1016/S0140-6736(18)30696-2
15
ChrysanthopoulouA.MitroulisI.ApostolidouE.ArelakiS.MikroulisD.KonstantinidisT.et al. (2014). Neutrophil extracellular traps promote differentiation and function of fibroblasts. J. Pathol.233, 294–307. doi: 10.1002/path.4359
16
ChumanevichA. A.CauseyC. P.KnuckleyB. A.JonesJ. E.PoudyalD.ChumanevichA. P.et al. (2011). Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am. J. Physiol. Gastrointest Liver Physiol.300 (6), G929–G938. doi: 10.1152/ajpgi.00435.2010
17
ClarkS. R.MaA. C.TavenerS. A.McDonaldB.GoodarziZ.KellyM. M.et al. (2007). Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat. Med.13 (4), 463–469. doi: 10.1038/nm1565
18
DąbrowskaD.JabłońskaE.GarleyM.Ratajczak-WronaW.IwaniukA. (2016). New Aspects of the Biology of Neutrophil Extracellular Traps. Scand. J. Immunol.84 (6), 317–322. doi: 10.1111/sji.12494
19
DarboussetR.ThomasG. M.MezouarS.FrereC.BonierR.MackmanN.et al. (2012). Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood120 (10), 2133–2143. doi: 10.1182/blood-2012-06-437772
20
DasuM. R.RiosvelascoA. C.JialalI. (2009). Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis202 (1), 76–83. doi: 10.1016/j.atherosclerosis.2008.04.010
21
de BoerO. J.LiX.TeelingP.MackaayC.PloegmakersH. J.van der LoosC. M.et al. (2013). Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb. Haemost.109, 290–297. doi: 10.1160/TH12-06-0425
22
de StoppelaarS. F.van TV. C.ClaushuisT. A.AlbersenB. J.RoelofsJ. J.van der PollT. (2014). Thrombocytopenia impairs host defense in gram-negative pneumonia-derived sepsis in mice. Blood124 (25), 3781–3790. doi: 10.1182/blood-2014-05-573915
23
DelboscS.AlsacJ. M.JourneC.LouedecL.CastierY.Bonnaure-MalletM.et al. (2011). Porphyromonas gingivalis participates in pathogenesis of human abdominal aortic aneurysm by neutrophil activation. Proof of concept in rats. PloS One6, e18679. doi: 10.1371/journal.pone.0018679
24
DucrouxC.Di MeglioL.LoyauS.DelboscS.BoisseauW.DeschildreC.et al. (2018). Thrombus Neutrophil Extracellular Traps Content Impair tPA-Induced Thrombolysis in Acute Ischemic Stroke. Stroke49, 754–757. doi: 10.1161/STROKEAHA.117.019896
25
ElkonK. B.SanterD. M. (2012). Complement, interferon and lupus. Curr. Opin. Immunol.24 (6), 665–670. doi: 10.1016/j.coi.2012.08.004
26
EngelmannB.MassbergS. (2013). Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol.7 (2), e32366. doi: 10.1371/journal.pone.0032366
27
FolcoE. J.MawsonT. L.VrommanA.Bernardes-SouzaB.FranckG.PerssonO.et al. (2018). Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1alpha and Cathepsin G. Arterioscler. Thromb. Vasc. Biol.38 (8), 1901–1912. doi: 10.1161/ATVBAHA.118.311150
28
FranckG.MawsonT. L.FolcoE. J.MolinaroR.RuvkunV.EngelbertsenD.et al. (2018). Roles of PAD4 and NETosis in Experimental Atherosclerosis and Arterial Injury: Implications for Superficial Erosion. Circ. Res.123, 33–42. doi: 10.1161/CIRCRESAHA.117.312494
29
FuchsT. A.BrillA.DuerschmiedD.SchatzbergD.MonestierM.MyersD. J.et al. (2010). Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. Sci. U. S. A.107 (36), 15880–15885. doi: 10.1073/pnas.1005743107
30
FuchsT. A.BhandariA. A.WagnerD. D. (2011). Histones induce rapid and profound thrombocytopenia in mice. Blood118, 3708–3714. doi: 10.1182/blood-2011-01-332676
31
GandoS. (2010). Microvascular thrombosis and multiple organ dysfunction syndrome. Crit. Care Med.38 (2 Suppl), S35–S42. doi: 10.1097/CCM.0b013e3181c9e31d
32
GaoW.XiongY.LiQ.YangH. (2017). Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics. Front. Physiol.8, 508. doi: 10.3389/fphys.2017.00508
33
GottsJ. E.MatthayM. A. (2016). Sepsis: pathophysiology and clinical management. BMJ353:i1585. doi: 10.1136/bmj.i1585
34
GroverS. P.MackmanN. (2018). Neutrophils, NETs, and immunothrombosis. Blood132 (13), 1360–1361. doi: 10.1182/blood-2018-08-868067
35
HiroseT.HamaguchiS.MatsumotoN.IrisawaT.SekiM.TasakiO.et al. (2014). Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream of critically ill patients. PloS One9 (11), e111755. doi: 10.1371/journal.pone.0111755
36
JenneC. N.KubesP. (2015). Platelets in inflammation and infection. Platelets26 (4), 286–292. doi: 10.3109/09537104.2015.1010441
37
JenneC. N.WongC. H.ZempF. J.McDonaldB.RahmanM. M.ForsythP. A.et al. (2013). Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe13 (2), 169–180. doi: 10.1016/j.chom.2013.01.005
38
Jimenez-AlcazarM.RangaswamyC.PandaR.BitterlingJ.SimsekY. J.LongA. T.et al. (2017). Host DNases prevent vascular occlusion by neutrophil extracellular traps. Science358, 1202–1206. doi: 10.1126/science.aam8897
39
KaplanM. J.RadicM. (2012). Neutrophil extracellular traps: double-edged swords of innate immunity. J. Immunol.189 (6), 2689–2695. doi: 10.4049/jimmunol.1201719
40
KnightJ. S.ZhaoW.LuoW.SubramanianV.O’DellA. A.YalavarthiS.et al. (2013). Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J. Clin. Invest.123 (7), 2981–2993. doi: 10.1172/JCI67390
41
KnightJ. S.SubramanianV.O’DellA. A.YalavarthiS.ZhaoW.SmithC. K.et al. (2015). Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann. Rheumatol. Dis.74 (12), 2199–2206. doi: 10.1136/annrheumdis-2014-205365
42
KolaczkowskaE.KubesP. (2013). Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol.13 (3), 159–175. doi: 10.1038/nri3399
43
KumarS.GuptaE.KaushikS.SrivastavaV. K.SaxenaJ.MehtaS.et al. (2019). Quantification of NETs formation in neutrophil and its correlation with the severity of sepsis and organ dysfunction. Clin. Chim. Acta495, 606–610. doi: 10.1016/j.cca.2019.06.008
44
LefflerJ.MartinM.GullstrandB.TydénH.LoodC.TruedssonL.et al. (2012). Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J. Immunol.188 (7), 3522–3531. doi: 10.4049/jimmunol.1102404
45
LelliottP. M.MomotaM.ShibaharaT.LeeM. S. J.SmithN. I.IshiiK. J.et al. (2020). Heparin induces neutrophil elastase-dependent vital and lytic NET formation. Int. Immunol.32 (5), 359–368. doi: 10.1093/intimm/dxz084
46
Lerner RGG. R. C. G. (1971). Stimulation of human leukocyte thromboplastic activity by endotoxin. Proc. Soc Exp. Biol. Med.138 (1), 145–148. doi: 10.3181/00379727-138-35848
47
LeshnerM.WangS.LewisC.ZhengH.ChenX. A.SantyL.et al. (2012). PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures. Front. Immunol.3, 307. doi: 10.3389/fimmu.2012.00307
48
LeyK.LaudannaC.CybulskyM. I.NoursharghS. (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol.7 (9), 678–689. doi: 10.1038/nri2156
49
LiangY.PanB.AlamH. B.DengQ.WangY.ChenE.et al. (2018). Inhibition of peptidylarginine deiminase alleviates LPS-induced pulmonary dysfunction and improves survival in a mouse model of lethal endotoxemia. Eur. J. Pharmacol.833, 432–440. doi: 10.1016/j.ejphar.2018.07.005
50
MatsunagaN.TsuchimoriN.MatsumotoT.IiM. (2011). TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol. Pharmacol.79, 34–41. doi: 10.1124/mol.110.068064
51
McDonaldB.DavisR. P.KimS. J.TseM.EsmonC. T.KolaczkowskaE.et al. (2017). Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. Blood129 (10), 1357–1367. doi: 10.1182/blood-2016-09-741298
52
MiddletonE. A.HeX. Y.DenormeF.CampbellR. A.NgD.SalvatoreS. P.et al. (2020). Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood136 (10), 1169–1179. doi: 10.1182/blood.2020007008
53
MorganB. P. (2016). The membrane attack complex as an inflammatory trigger. Immunobiology221 (6), 747–751. doi: 10.1016/j.imbio.2015.04.006
54
MussbacherM.SalzmannM.BrostjanC.HoeselB.SchoergenhoferC.DatlerH.et al. (2019). Cell Type-Specific Roles of NF-κB Linking Inflammation and Thrombosis. Front. Immunol.10, 85. doi: 10.3389/fimmu.2019.00085
55
NarasarajuT.YangE.SamyR. P.NgH. H.PohW. P.LiewA. A.et al. (2011). Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am. J. Pathol.179 (1), 199–210. doi: 10.1016/j.ajpath.2011.03.013
56
NealM. D.JiaH.EyerB.GoodM.GuerrieroC. J.SodhiC. P.et al. (2013). Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors. PloS One8 (6), , e65779. doi: 10.1371/journal.pone.0065779
57
ObiA. T.AndraskaE.KanthiY.KessingerC. W.ElflineM.LukeC.et al. (2017). Endotoxaemia-augmented murine venous thrombosis is dependent on TLR-4 and ICAM-1, and potentiated by neutropenia. Thromb. Haemost.117 (2), 339–348. doi: 10.1160/TH16-03-0218
58
PapayannopoulosV. (2018). Neutrophil extracellular traps in immunity and disease. Nat. Rev. Immunol.18 (2), 134–147. doi: 10.1038/nri.2017.105
59
PerdomoJ.LeungH.AhmadiZ.YanF.ChongJ.PassamF. H.et al. (2019). Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat. Commun.10 (1), 1322. doi: 10.1038/s41467-019-09160-7
60
PouplardC.MayM. A.IochmannS.AmiralJ.VissacA. M.MarchandM.et al. (1999). Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Circulation99 (19), 2530–2536. doi: 10.1161/01.cir.99.19.2530
61
PowersM. E.BeckerR. E.SailerA.TurnerJ. R.BubeckW. J. (2015). Synergistic Action of Staphylococcus aureus alpha-Toxin on Platelets and Myeloid Lineage Cells Contributes to Lethal Sepsis. Cell Host Microbe17 (6), 775–787. doi: 10.1016/j.chom.2015.05.011
62
RabinovitchM. (2016). NETs Activate Pulmonary Arterial Endothelial Cells. Arterioscler. Thromb. Vasc. Biol.36, 2035–2037. doi: 10.1161/ATVBAHA.116.308206
63
RiceT. W.WheelerA. P.BernardG. R.VincentJ.AngusD. C.AikawaN.et al. (2010). A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med.38, 1685–1694. doi: 10.1097/CCM.0b013e3181e7c5c9
64
RuddK. E.JohnsonS. C.AgesaK. M.ShackelfordK. A.TsoiD.KievlanD. R.et al. (2020). Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet395, 200–211. doi: 10.1016/S0140-6736(19)32989-7
65
SaffarzadehM.JuenemannC.QueisserM. A.LochnitG.BarretoG.GaluskaS. P.et al. (2012). Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PloS One7 (2), e32366. doi: 10.1371/journal.pone.0032366
66
SaitohT.KomanoJ.SaitohY.MisawaT.TakahamaM.KozakiT.et al. (2012). Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1. Cell Host Microbe12 (1), 109–116. doi: 10.1016/j.chom.2012.05.015
67
SandquistM.WongH. R. (2014). Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Expert. Rev. Clin. Immunol.10 (10), 1349–1356. doi: 10.1586/1744666X.2014.949675
68
SchattnerM. (2019). Platelet TLR4 at the crossroads of thrombosis and the innate immune response. J. Leukocyte. Biol.105 (5), 873–880. doi: 10.1002/JLB.MR0618-213R
69
SemeraroF.AmmolloC. T.MorrisseyJ. H.DaleG. L.FrieseP.EsmonN. L.et al. (2011). Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood118, 1952–1961. doi: 10.1182/blood-2011-03-343061
70
SingerM.DeutschmanC. S.SeymourC. W.Shankar-HariM.AnnaneD.BauerM.et al. (2016). The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama315, 801–810. doi: 10.1001/jama.2016.0287
71
SmadjaD. M. (2014). Neutrophils as new conductors of vascular homeostasis. J. Thromb. Haemost.12 (7), 1166–1169. doi: 10.1111/jth.12585
72
SunY.ChenC.ZhangX.WangS.ZhuR.ZhouA.et al. (2020). Heparin improves alveolarization and vascular development in hyperoxia-induced bronchopulmonary dysplasia by inhibiting neutrophil extracellular traps. Biochem. Biophys. Res. Commun.522 (1), 33–39. doi: 10.1016/j.bbrc.2019.11.041
73
SurewaardB.ThanabalasuriarA.ZengZ.TkaczykC.CohenT. S.BardoelB. W.et al. (2018). alpha-Toxin Induces Platelet Aggregation and Liver Injury during Staphylococcus aureus Sepsis. Cell Host Microbe24 (2), 271–284.e3. doi: 10.1016/j.chom.2018.06.017
74
ThomasG. M.CarboC.CurtisB. R.MartinodK.MazoI. B.SchatzbergD.et al. (2012). Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood119 (26), 6335–6343. doi: 10.1182/blood-2012-01-405183
75
UrbanC. F.ReichardU.BrinkmannV.ZychlinskyA. (2006). Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell Microbiol.8 (4), 668–676. doi: 10.1111/j.1462-5822.2005.00659.x
76
van der MeijdenP.HeemskerkJ. (2019). Platelet biology and functions: new concepts and clinical perspectives. Nat. Rev. Cardiol.16 (3), 166–179. doi: 10.1038/s41569-018-0110-0
77
VorobjevaN. V.ChernyakB. V. (2020). NETosis: Molecular Mechanisms, Role in Physiology and Pathology. Biochem. (Mosc).85 (10), 1178–1190. doi: 10.1134/S0006297920100065
78
WangY.WysockaJ.SayeghJ.LeeY. H.PerlinJ. R.LeonelliL.et al. (2004). Human PAD4 regulates histone arginine methylation levels via demethylimination. Science306 (5694), 279–283. doi: 10.1126/science.1101400
79
WangH.WangC.ZhaoM. H.ChenM. (2015). Neutrophil extracellular traps can activate alternative complement pathways. Clin. Exp. Immunol.181 (3), 518–527. doi: 10.1111/cei.12654
80
WangH.ShaL. L.MaT. T.ZhangL. X.ChenM.ZhaoM. H. (2016). Circulating Level of Neutrophil Extracellular Traps Is Not a Useful Biomarker for Assessing Disease Activity in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. PloS One11 (2), e0148197. doi: 10.1371/journal.pone.0148197
81
XuJ.ZhangX.PelayoR.MonestierM.AmmolloC. T.SemeraroF.et al. (2009). Extracellular histones are major mediators of death in sepsis. Nat. Med.15 (11), 1318–1321. doi: 10.1038/nm.2053
82
YanY.YangH.HuX.ZhangZ.GeS.XuZ.et al. (2019). Kindlin-3 in platelets and myeloid cells differentially regulates deep vein thrombosis in mice. Aging (Albany NY)11 (17), 6951–6959. doi: 10.18632/aging.102229
83
YangJ.JiangH.YangJ.DingJ. W.ChenL. H.LiS.et al. (2009). Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway. Mol. Cell. Biochem.330 (1-2), 39–46. doi: 10.1007/s11010-009-0098-1
84
YippB. G.PetriB.SalinaD.JenneC. N.ScottB. N.ZbytnuikL. D.et al. (2012). Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. Nat. Med.18 (9), 1386–1393. doi: 10.1038/nm.2847
85
YousefiS.MihalacheC.KozlowskiE.SchmidI.SimonH. U. (2009). Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ.16 (11), 1438–1444. doi: 10.1038/cdd.2009.96
86
YuenJ.PlutheroF. G.DoudaD. N.RiedlM.CherryA.UlanovaM.et al. (2016). NETosing Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways. Front. Immunol.7, 137. doi: 10.3389/fimmu.2016.00137
Summary
Keywords
sepsis, thrombosis, neutrophil extracellular traps, platelets, complement
Citation
Chen Z, Zhang H, Qu M, Nan K, Cao H, Cata JP, Chen W and Miao C (2021) Review: The Emerging Role of Neutrophil Extracellular Traps in Sepsis and Sepsis-Associated Thrombosis. Front. Cell. Infect. Microbiol. 11:653228. doi: 10.3389/fcimb.2021.653228
Received
14 January 2021
Accepted
25 February 2021
Published
17 March 2021
Volume
11 - 2021
Edited by
Meihong Deng, The Ohio State University, United States
Reviewed by
Ailing Lu, Feinstein Institute for Medical Research, United States; Hai Huang, The Ohio State University, United States
Updates
Copyright
© 2021 Chen, Zhang, Qu, Nan, Cao, Cata, Chen and Miao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Juan P. Cata, jcata@mdanderson.org; Wankun Chen, chenwank@163.com; Changhong Miao, miaochangh@163.com
†These authors have contributed equally to this work and share first authorship
This article was submitted to Microbes and Innate Immunity, a section of the journal Frontiers in Cellular and Infection Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.